REGULATION OF CRISPR AND GENE EDITING TECHNOLOGIES

1. INTRODUCTION

CRISPR-Cas systems and other gene-editing technologies enable targeted changes to genetic material. Their applications include treatment of inherited diseases, cancer research, agricultural improvement, and the development of disease-resistant organisms. However, unintended genetic changes, heritable modifications, ecological effects, and ethical concerns require effective legal oversight.

In India, regulation depends on the application involved. Human gene therapies are governed by drug, clinical-trial, and biosafety requirements, while gene-edited plants are subject to the environmental biosafety framework and specific guidelines. The principal regulatory objective is to promote scientific innovation while protecting human health, biodiversity, informed consent, and public welfare.

2. LEGAL AND REGULATORY FRAMEWORK IN INDIA

A. ENVIRONMENTAL AND BIOSAFETY LEGISLATION

The Environment (Protection) Act, 1986, and the Rules for the Manufacture, Use, Import, Export and Storage of Hazardous Microorganisms/Genetically Engineered Organisms or Cells, 1989, establish India's principal framework for regulating genetically engineered organisms.

The Institutional Biosafety Committee (IBSC), Review Committee on Genetic Manipulation (RCGM), and Genetic Engineering Appraisal Committee (GEAC) perform functions according to the applicable rules and regulatory pathway.

In 2022, the Ministry of Environment, Forest and Climate Change exempted qualifying SDN-1 and SDN-2 genome-edited plants, free of exogenous introduced DNA, from Rules 7–11 of the 1989 Rules. The Department of Biotechnology subsequently issued the Guidelines for the Safety Assessment of Genome Edited Plants, 2022, and associated standard operating procedures. This is a conditional, plant-specific exemption, not a general exemption for every gene-edited organism. Other applicable laws continue to apply.

B. HUMAN GENE THERAPY

The National Guidelines for Gene Therapy Product Development and Clinical Trials, 2019, issued by the relevant Indian authorities, guide the development and clinical evaluation of gene therapy products.

The Drugs and Cosmetics Act, 1940, and New Drugs and Clinical Trials Rules, 2019, apply where relevant to investigational gene therapies. Ethical review, informed consent, biosafety controls, appropriate regulatory permissions, and monitoring of adverse events are essential.

C. INTERNATIONAL GOVERNANCE

The World Health Organization's 2021 human genome-editing governance framework recommends oversight, transparent reporting, international cooperation, and measures to prevent unethical or unregistered research. These recommendations provide influential guidance but do not independently replace domestic legislation.

3. IMPORTANT CASE LAWS

1. Gene Campaign v. Union of India (2024 INSC 545) — Direct authority on genetically engineered organisms; analogous to CRISPR regulation.

The Supreme Court delivered a split verdict concerning the environmental release of genetically modified mustard, DMH-11. The judges disagreed over the validity of the approval, but agreed that regulatory decisions concerning genetically modified organisms are subject to judicial review. The Court directed the Union Government to formulate a national policy on GM crops in consultation with stakeholders, including state governments and scientific experts. The judgment is significant for transparency, biosafety assessment, expert independence, and precaution in biotechnology governance.

2. Aruna Rodrigues v. Union of India — Direct authority on GM-crop oversight; analogous to gene-edited crops.

The Supreme Court's proceedings concerning genetically modified crops emphasised the importance of scientific assessment, regulatory supervision, and environmental safeguards. The litigation contributed to scrutiny of field trials and approval procedures. Its principles are relevant when evaluating whether gene-editing decisions adequately consider ecological risks.

3. Vellore Citizens' Welfare Forum v. Union of India (1996) — Analogous environmental authority.

The Supreme Court recognised the precautionary principle and the polluter-pays principle as essential elements of Indian environmental law. These principles support risk assessment and preventive safeguards where gene-edited organisms may cause serious or irreversible environmental harm.

4. A.P. Pollution Control Board v. Prof. M.V. Nayudu (1999) — Analogous scientific-governance authority.

The Supreme Court discussed the difficulties courts face when evaluating complex scientific and environmental questions. The decision underscores the need for credible expert assessment and scientifically informed regulatory decisions in biotechnology matters.

5. Association for Molecular Pathology v. Myriad Genetics, Inc. (2013) — Analogous intellectual-property authority.

The United States Supreme Court held that naturally occurring DNA is not patentable merely because it has been isolated, while synthetically created complementary DNA may be patentable in the circumstances considered. Although not a gene-editing safety case, the judgment is relevant to biotechnology innovation, patent strategy, and the distinction between natural genetic material and human-created inventions.

6. He Jiankui case, Shenzhen Nanshan District People's Court (2019) — Direct human gene-editing enforcement example.

A Chinese court sentenced researcher He Jiankui to three years' imprisonment and imposed a fine for illegally conducting human embryo gene-editing experiments that resulted in the birth of gene-edited children. The court found serious violations involving medical regulation, research ethics, and documentation. The case illustrates the consequences of undertaking heritable human genome editing without adequate authorisation and safeguards.

4. KEY COMPLIANCE REQUIREMENTS

Researchers and institutions should identify the applicable regulatory category before beginning gene-editing work. They should obtain necessary biosafety and ethics approvals, document the editing method, assess unintended genetic changes, maintain secure research records, and establish appropriate containment and waste-management procedures.

Human clinical research additionally requires scientifically justified protocols, informed consent, regulatory authorisation, safety monitoring, and appropriate follow-up. Heritable editing raises particularly serious concerns because modifications may affect future generations who cannot consent.

Agricultural developers must follow the applicable plant-specific pathway, establish that eligibility conditions for any exemption are met, and comply with remaining requirements for variety development, environmental release, food safety, and labelling.

5. CONCLUSION

CRISPR and gene-editing regulation requires a proportionate approach that distinguishes medical applications, agricultural development, contained research, and heritable human interventions. Indian legislation combines environmental biosafety controls with specific pathways for qualifying genome-edited plants and separate regulation of human gene therapies. Judicial decisions reinforce precaution, transparency, scientific accountability, and review of regulatory decisions. Effective governance must therefore ensure that innovation proceeds within legally authorised, ethically responsible, and scientifically defensible limits.